Sponsor

Cogent Biosciences, Inc.

Clinical research sponsor

Published trials4

Recruiting shown2

Roles1

SourceClinicalTrials.gov

Clinical trials

4 shown

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid TumorsNCT07383506 · lead sponsor · 2026-07-23

RECRUITING

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid TumorsNCT07361562 · lead sponsor · 2025-12-30

RECRUITING

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid TumorsNCT06777316 · lead sponsor · 2025-01-22

ACTIVE_NOT_RECRUITING

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor CancersNCT03680560 · lead sponsor · 2019-03-13

TERMINATED

Sponsor roles

lead sponsor4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.